
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.
The phase 1b study will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.